Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Abstract Text:

Ann M Reynolds,Wei Xia,Mark D Holmes,Sandra J Hodge,Sergei Danilov,David T Curiel,Nicholas W Morrell,Paul N Reynolds,

Idiopathic pulmonary arterial hypertension (PAH) is characterized by proliferation of pulmonary vascular endothelial and smooth muscle cells causing increased vascular resistance and right heart failure. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are believed to cause the familial form of the disease. Reduced expression of BMPR2 is also noted in secondary PAH. Recent advances in the therapy of PAH have improved quality of life and survival, but many patients continue to do poorly. The possibility of treating PAH via improving BMPR2 signaling is thus a rational consideration. Such an approach could be synergistic with or additive to current treatments. We developed adenoviral vectors containing the BMPR2 gene. Transfection of cells in vitro resulted in upregulation of SMAD signaling and reduced cell proliferation. Targeted delivery of vector to the pulmonary vascular endothelium of rats substantially reduced the pulmonary hypertensive response to chronic hypoxia, as reflected by reductions in pulmonary artery and right ventricular pressures, right ventricular hypertrophy, and muscularization of distal pulmonary arterioles. These data provide further evidence for a role for BMPR2 in PAH and provide a rationale for the development of therapies aimed at improving BMPR2 signaling.

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Publishing Authors By Initials

AM Reynolds,W Xia,MD Holmes,SJ Hodge,S Danilov,DT Curiel,NW Morrell,PN Reynolds,

For similar animals: chordata: vertebrates: mammals: rodentia: muridae: murinae: rats research abstracts see: animals: chordata: vertebrates: mammals: rodentia: muridae: murinae: rats research

PUBMED ID PMID:

MEDLINE DATE:

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of physiology. Lung cellular and

VOLUME: 292

Page Numbers: L1182-92

Journal Abbreviation: Am. J. Physiol. Lung Cell Mol.

ISSN: 1040-0605

DAY: 2

MONTH: 02

YEAR: 2007

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100901229

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Keywords Mesh Terms:

KEYWORDS: Rats

MESH TERMS: physiopathology

Chemical & Substance for Abstract: Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Information

Substance Name: Bone Morphogenetic Protein Receptors, Ty

Registry Number: EC 2.7.1.37

Grant and Affiliation Information for Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.

AFFILIATION: Lung Research Laboratory, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Country: United States

AGENCY: United States NHLBI

GRANT: R01-HL-67962-01

ACRONYM: HL

MEDLINETA: Am J Physiol Lung Cell Mol Phy

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension Related Publications

• A description of the preterm fetal sheep systemic and central responses to maternal general anesthesia.
• A review of delay-discounting research with humans: relations to drug use and gambling.
• Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
• Age-related differences in the lifestyle regularity of seniors experiencing bereavement, care-giving, insomnia, and advancement into old-old age.
• An Intent-to-Treat Method for Enhancing Analysis of Clinical Trials with Rescue Medication: A Mixed-Model Approach.
• Anne L. Davis, m.d.: 1925-2003.
• Barbaloin in aloe species.
• Birth characteristics and risk of neuroblastoma in young children.
• Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.
• Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study.
• Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age.
• Ethical considerations in the conduct of electronic surveillance research.
• Event perception: a mind-brain perspective.
• Expanding the usefulness of Interpersonal Psychotherapy (IPT) for depressed elders with co-morbid cognitive impairment.
• Feeding rumen-inert fats differing in their degree of saturation decreases intake and increases plasma concentrations of gut peptides in lactating dairy cows.
• Flow cytometric analysis of adherence of Porphyromonas gingivalis to oral epithelial cells.
• Hemlock Alkaloids in Aloes. Occurrence and Distribution of gamma-Coniceine.
• Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
• Kgp and RgpB, but not RgpA, are important for Porphyromonas gingivalis virulence in the murine periodontitis model.
• Mitochondrial trafficking and morphology in healthy and injured neurons.
• Placental growth throughout the last two thirds of pregnancy in sheep: vascular development and angiogenic factor expression.
• Plasma concentrations of gut peptides in dairy cattle increase after calving.
• Sleep in healthy seniors: a diary study of the relation between bedtime and the amount of sleep obtained.
• Stimulus-specific competitive selection in macaque extrastriate visual area V4.
• Synthesis and biological evaluation of thiazolidine-2-one 1,1-dioxide as inhibitors of Escherichia coli beta-ketoacyl-ACP-synthase III (FabH).
• Temporal resolution for the perception of features and conjunctions.
• The Opi1p transcription factor affects expression of FLO11, mat formation, and invasive growth in Saccharomyces cerevisiae.
• Vaccination with recombinant adhesins from the RgpA-Kgp proteinase-adhesin complex protects against Porphyromonas gingivalis infection.
• p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho.
• p120-catenin: Past and present.